BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference
BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium
Skyharbour Announces Additional Uranium Property Staking Increasing Total Portfolio to Over 662,000 Hectares in the Athabasca Basin, Saskatchewan
Homerun Resources Inc. Announces Full Mining Permit and Finalization of the Definitive Lease Agreement With CBPM
Brunswick Exploration Announces Inferred Mineral Resource of 52.2Mt at 1.08% Li2O at Mirage with Additional Exploration Target
